CLAIMS

1. A compound represented by the formula

$$\begin{array}{c|c}
X & R^2 \\
\hline
A & N & R^3
\end{array}$$
(1)

wherein Ring A represents an optionally substituted pyridine ring, X represents an electron-attracting group, Y represents an optionally substituted divalent C_{1-6} chained hydrocarbon group, R^1 represents an optionally substituted hydrocarbon group, and R^2 and R^3 each independently represent a hydrogen atom, an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group, or R^2 and R^3 may form an optionally substituted ring together with an adjacent nitrogen atom, or a salt thereof.

2. The compound according to claim 1 which is a compound represented by the formula

$$\begin{array}{c|c}
X & R^2 \\
N & N & R^3
\end{array}$$

15

5

10

wherein Ring A" represents a pyridine ring which may have 1 to 3 substituents selected from a C_{1-4} alkyl group

and a mono-, di- or tri-halogeno- C_{1-4} alkyl group and other symbols are as defined in claim 1, or a salt thereof.

- 3. The compound according to claim 1, wherein \boldsymbol{X} is a nitrile group.
- 4. The compound according to claim 1, wherein Y is -CH=CH- or $-(CH_2)_2-$.

5

10

- 5. The compound according to claim 1, wherein R^1 is (1) a C_{5-7} cycloalkyl group optionally fused with a benzene ring, (2) a C_{7-19} aralkyl group, (3) a 5- or 6-membered heterocyclic ring- C_{1-4} alkyl group or (4) a C_{6-14} aryloxy- C_{1-4} alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C_{1-4} alkyl group, a mono-, di- or tri-halogeno- C_{1-4} alkyl group and a C_{1-4} alkoxy group.
- 6. The compound according to claim 1, wherein one of R² and R³ is a hydrogen atom or a C₁₋₄ alkyl group, and the other is a 5- or 6-membered heterocyclic group, a C₆₋₁₄ aryl group, a C₇₋₁₉ aralkyl group, a C₃₋₁₀ cycloalkyl group, a 5- or 6-membered heterocyclic ring-C₁₋₄ alkyl group or C₁₋₆ alkyl group, each of which may have 1 to 4 substituents selected from a halogen atom, a C₁₋₄ alkyl group, a mono-, di- or tri-halogeno-C₁₋₄ alkyl group, a C₁₋₄ alkoxy group, a C₁₋₄ alkoxy-carbonyl group, a cyano group, a C₁₋₄ alkyl-carbonylamino group and a hydroxy group; or R² and R³, together with an adjacent nitrogen atom, form a 5- or 6- membered nitrogen-containing heterocyclic ring optionally

containing 1 to 3 hetero atoms selected from an oxygen atom, a sulfur atom and a nitrogen atom in addition to carbon atoms and one nitrogen atom, in which the nitrogen-containing heterocyclic ring may have 1 to 4 substituents selected from a halogen atom, a C_{1-4} alkyl group, a mono-, di- or tri-halogeno- C_{1-4} alkyl group, a C_{1-4} alkoxy group and a C_{1-4} alkoxy-carbonyl group.

5

10

- 7. (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3,4-dimethoxyphenyl)prop-2-enamide,
- $(2E)-3-\{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl\}-N-(3,4-dimethylphenyl)prop-2-enamide,$
- (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4
 tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}
 N-methyl-N-phenylprop-2-enamide,
 - (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(3-methylphenyl)prop-2-enamide,
- 20 (2E)-3-{3-cyano-4,6-dimethyl-1-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl}-N-(4-hydroxy-3-methoxyphenyl)prop-2-enamide, or salts thereof.
 - 8. A prodrug of the compound according to claim 1.
- 9. A medicine comprising the compound according to

claim 1 or a prodrug thereof.

5

20

- 10. The medicine according to claim 9 which is a vanilloid receptor agonist.
- 11. The vanilloid receptor agonist according to claim
 10 which is for local administration.
 - 12. The vanilloid receptor agonist according to claim
 10 which is an agent for preventing and/or treating
 overactive bladder.
- 13. The vanilloid receptor agonist according to claim10 which is an analgesic.
 - 14. A method of preventing and/or treating overactive bladder, comprising administering to a mammal in need an effective amount of the compound according to claim 1 or a prodrug thereof.
- 15. An analgesic method comprising administering to a mammal in need an effective amount of the compound according to claim 1 or a prodrug thereof.
 - 16. Use of the compound according to claim 1 or a prodrug thereof for manufacturing an agent for preventing and/or treating overactive bladder.
 - 17. Use of the compound according to claim 1 or a prodrug thereof for manufacturing an analgesic.